Bautista Eduardo R, Bernardo Pocholo Carlo R, Manapat Adrian E, Kaw Leoncio L, Cabasa Alduz Inri S
Division of Thoracic, Cardiac and Vascular Surgery, Department of Surgery, College of Medicine and Philippine General Hospital, University of the Philippines Manila.
Acta Med Philipp. 2024 Nov 29;58(21):40-48. doi: 10.47895/amp.vi0.8542. eCollection 2024.
To describe the treatment outcomes of patients who underwent Percutaneous Transluminal Angioplasty (PTA) for Central Vein Occlusive Disease (CVOD) in end-stage kidney disease and determine the association between patient profile and treatment outcomes.
A single-institution, retrospective review of patients aged 18 and above with end-stage kidney disease who underwent PTA for CVOD in the University of the Philippines - Philippine General Hospital (UP-PGH) from January 1, 2013, to December 31, 2022, was performed. These patients' demographic and clinical profiles were evaluated using means, frequencies, and percentages. The relationship between patient profile and success of PTA was assessed using Chi-square and Mann-Whitney U tests.
One hundred one patients were included in the study. Eighty-two had a first intervention, and 19 had a recurrent first intervention. The mean age was 49.8 years, with forty-six (45.5%) males and fifty-five (54.5%) females. The most common comorbidity was hypertension (59.4%). This was followed by diabetes (35.6%), chronic glomerulonephritis (18.8%), and NSAID nephropathy (4.9%). Other comorbidities include lupus nephritis, urate nephropathy, and polycystic kidney disease. The interval between symptoms and intervention ranged from two weeks to ninety-six weeks. Eleven patients (10.9%) had an arterio-venous fistula (AVF) before initiating dialysis and did not have a history of dialysis catheter use. Temporary catheters comprise most of the central vein catheters (CVC) (84.2%), while tunneled catheters were a minority (8.9%). The overall central line insertions of one hundred one patients were one hundred fifty-five, most via the right internal jugular vein (86%). There was a total of one hundred twenty-seven lesions seen during venography. Most of these lesions were in the left Innominate vein (38.6%, 39/101) and the right innominate vein (32.7%, 33/101). The most common type of lesion was stenosis (47.5%), followed by abrupt occlusions (31.7%) and tapered occlusions (20.8%). The overall success rate of PTA was 74.2%. In the second intervention for recurrence (n=19), the success rate was 78.9% (15/19). Third-time intervention in three patients was all successful. The success rate in stenotic, tapered, and abrupt lesions were 100%, 85.7%, and 28.1%, respectively. Symptom-free intervals ranged from twelve to one hundred ninety-two weeks. After a failed intervention, a new fistula or graft was the most common access option (50%). This was followed by central catheter (38.5%), venous bypass (7.7%), and peritoneal dialysis catheter (3.8%). Morbidity was 0.99%. The in-hospital mortality was zero.
Overall PTA success rate for non-recurrent and first operation of recurrent patients with CVOD was high (74%). Stenotic type of lesions were the best vessels to dilate. Failure of PTA was directly related to previous right subclavian catheter insertion, multiple central vein catheter insertions, lesions in the right innominate vein, and an abrupt type of central vein occlusion. The current strategy of PTA for CVOD is both safe and effective. Early AVF creation can prevent patients from requiring multiple catheter insertions and developing CVOD. The right internal jugular vein is the optimal choice for access, while subclavian vein access should be avoided.
描述终末期肾病患者经皮腔内血管成形术(PTA)治疗中心静脉闭塞性疾病(CVOD)的治疗效果,并确定患者特征与治疗效果之间的关联。
对2013年1月1日至2022年12月31日在菲律宾大学菲律宾总医院(UP-PGH)接受CVOD的PTA治疗的18岁及以上终末期肾病患者进行单机构回顾性研究。使用均值、频率和百分比评估这些患者的人口统计学和临床特征。使用卡方检验和曼-惠特尼U检验评估患者特征与PTA成功率之间的关系。
101例患者纳入研究。82例为首次干预,19例为复发性首次干预。平均年龄为49.8岁,男性46例(45.5%),女性55例(54.5%)。最常见的合并症是高血压(59.4%)。其次是糖尿病(35.6%)、慢性肾小球肾炎(18.8%)和非甾体抗炎药肾病(4.9%)。其他合并症包括狼疮性肾炎、尿酸盐肾病和多囊肾病。症状出现至干预的间隔时间为2周至96周。11例患者(10.9%)在开始透析前有动静脉内瘘(AVF),且无透析导管使用史。临时导管占中心静脉导管(CVC)的大部分(84.2%),而隧道式导管占少数(8.9%)。101例患者的中心静脉置管总数为155次,大多数通过右颈内静脉(86%)。静脉造影共发现127个病变。这些病变大多数位于左无名静脉(38.6%,39/101)和右无名静脉(32.7%,33/101)。最常见的病变类型是狭窄(47.5%),其次是突然闭塞(31.7%)和逐渐变细的闭塞(20.8%)。PTA的总体成功率为74.2%。在复发性患者的第二次干预(n = 19)中,成功率为78.9%(15/19)。3例患者的第三次干预均成功。狭窄、逐渐变细和突然病变的成功率分别为100%、85.7%和28.1%。无症状间隔时间为12周至192周。干预失败后,新的内瘘或移植物是最常见选择的通路(50%)。其次是中心静脉导管(38.5%)、静脉旁路(7.7%)和腹膜透析导管(3.8%)。发病率为0.99%。住院死亡率为零。
CVOD非复发性和复发性患者首次手术的PTA总体成功率较高(74%)。狭窄类型的病变是最适合扩张的血管。PTA失败与既往右锁骨下静脉置管、多次中心静脉置管、右无名静脉病变以及中心静脉突然闭塞类型直接相关。目前CVOD的PTA策略安全有效。早期建立AVF可防止患者需要多次置管并发生CVOD。右颈内静脉是通路的最佳选择,应避免使用锁骨下静脉通路。